3 Cathie Wood Investments That Could Deliver Superior Returns
Cathie Wood, the CEO of Ark Investment, has made a name for herself by betting on cutting-edge technology with financial technology stocks, or fintechs, and biotechnology growth stocks making up a significant part of her exchange-traded funds (ETFs). While many growth stocks fell out of favor the past two years, her flagship ARK Innovation ETF (NYSEMKT: ARKK) is up more than 44% so far this year.
Two of the Wood investments that I believe will deliver long-term superior returns are gene-editing biotechs, Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP), while another is the fintech Block (NYSE: SQ). All three companies are well off their 52-week highs, but have seen their shares rise so far this year.
Here's why each of these stocks could deliver elite returns.
Source Fool.com
Intellia Therapeutics Inc Stock
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Intellia Therapeutics Inc.
With a target price of 60 € there is potential for a 173.85% increase which would mean more than doubling the current price of 21.91 € for Intellia Therapeutics Inc.
